Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

Healthcare Biotechnology
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

BELLUS Health Inc
Bullboard Posts
User Avatar Image
(11)
•••
Comment by bilarooon Jun 01, 2016 10:16am
179 Views
Post# 24922795

RE:RE:RE:RE:RE:RE:Very tight float

RE:RE:RE:RE:RE:RE:Very tight float Thanks for that, just read it. Just so there's no confusion here is what it says......

The Company now has approximately 54.7 million common shares outstanding and 65.7 million common shares on a fully diluted basis. Dilution items include approximately 4.7 million common shares issuable under the stock option plan and 6.4 million common shares issuable upon the exercise by Pharmascience of its right to exchange its 10.4% interest in the limited partnership carrying out BELLUS Health's activities (the Exchange Right). On or after September 30, 2016, BELLUS Health has the right, which the Company expects to exercise, to force the conversion of the Pharmascience Exchange Right.

 


Read more at https://www.stockhouse.com/news/press-releases/2016/01/01/bellus-health-announces-scheduled-settlement-of-convertible-notes#WuGifo2ZvuFm7LOc.99
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities